Ziyu Han1,2,3,4, Wenting Shang2, Xiaoyuan Liang1,4, Hao Yan2, Min Hu1,4, Li Peng2, Hongmei Jiang2, Chihua Fang5,6, Kun Wang7, Jie Tian8,9,10,11. 1. Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China. 2. CAS Key Laboratory of Molecular Imaging, the State Key Laboratory of Management and control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China. 3. University of Chinese Academy of Sciences, Beijing, 100080, China. 4. Guangdong Provincial Clinical and Engineering Center of Digital Medicine, Guangzhou, 510280, China. 5. Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China. fangch_dr@163.com. 6. Guangdong Provincial Clinical and Engineering Center of Digital Medicine, Guangzhou, 510280, China. fangch_dr@163.com. 7. CAS Key Laboratory of Molecular Imaging, the State Key Laboratory of Management and control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China. kun.wang@ia.ac.cn. 8. CAS Key Laboratory of Molecular Imaging, the State Key Laboratory of Management and control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China. jie.tian@ia.ac.cn. 9. University of Chinese Academy of Sciences, Beijing, 100080, China. jie.tian@ia.ac.cn. 10. CAS Center for Excellence in Brain Science and Intelligence Technology, Institute of Automation, Chinese Academy of Sciences, Beijing, China. jie.tian@ia.ac.cn. 11. CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Zhongguancun East Road #95, Haidian Dist, Beijing, 100190, China. jie.tian@ia.ac.cn.
Abstract
PURPOSE: Pancreatic cancer is still associated with a poor outcome and low patient quality of life, which are mainly attributed to the late detection and requirement of distal pancreatectomy with extended resection of pancreatic tumors. Therefore, novel strategies for early screening and precise tumor resection are urgently needed. In this study, we evaluated the feasibility of a low-density lipoprotein receptor (LDLR)-targeted small-molecule contrast agent (peptide-22-Cy7) for early screening with photoacoustic tomography and near-infrared (NIR) imaging as guided surgical navigation to achieve precise resection. PROCEDURE: Normal pancreatic cells (HPDE6-C7) and cancer cells (PANC-1) were respectively used in the in vitro targeting evaluations. The ability of peptide-22-Cy7 for preoperative in vivo pancreatic tumor detection was investigated in a mouse orthotopic pancreatic cancer model (n = 10) using photoacoustic tomography; 18 tumor-bearing mice were further divided into three groups for different treatments. After intravenous injection of peptide-22-Cy7, surgical navigation was conducted through laparotomy. Histopathological analysis was used to further confirm the tumor area and the state of surgical margins. RESULTS: Flow cytometry demonstrated that peptide-22 is highly specific to pancreatic cancer cells, with a fluorescence intensity of approximately 87.3 %. Orthotopic pancreatic tumors with a size of 4 mm could be accurately detected by photoacoustic tomography. Surgical navigation effectively achieved R0 resection and minimized the range of resection, which led to increased body weight of the mice following surgery. CONCLUSION: Overall, our newly developed targeted contrast agent facilitated the accurate positioning and resection of pancreatic tumors. Photoacoustic tomography and optical imaging-guided surgical navigation may be a novel direction for improving the survival, quality of life, and disease management of pancreatic cancer patients.
PURPOSE:Pancreatic cancer is still associated with a poor outcome and low patient quality of life, which are mainly attributed to the late detection and requirement of distal pancreatectomy with extended resection of pancreatic tumors. Therefore, novel strategies for early screening and precise tumor resection are urgently needed. In this study, we evaluated the feasibility of a low-density lipoprotein receptor (LDLR)-targeted small-molecule contrast agent (peptide-22-Cy7) for early screening with photoacoustic tomography and near-infrared (NIR) imaging as guided surgical navigation to achieve precise resection. PROCEDURE: Normal pancreatic cells (HPDE6-C7) and cancer cells (PANC-1) were respectively used in the in vitro targeting evaluations. The ability of peptide-22-Cy7 for preoperative in vivo pancreatic tumor detection was investigated in a mouseorthotopic pancreatic cancer model (n = 10) using photoacoustic tomography; 18 tumor-bearing mice were further divided into three groups for different treatments. After intravenous injection of peptide-22-Cy7, surgical navigation was conducted through laparotomy. Histopathological analysis was used to further confirm the tumor area and the state of surgical margins. RESULTS: Flow cytometry demonstrated that peptide-22 is highly specific to pancreatic cancer cells, with a fluorescence intensity of approximately 87.3 %. Orthotopic pancreatic tumors with a size of 4 mm could be accurately detected by photoacoustic tomography. Surgical navigation effectively achieved R0 resection and minimized the range of resection, which led to increased body weight of the mice following surgery. CONCLUSION: Overall, our newly developed targeted contrast agent facilitated the accurate positioning and resection of pancreatic tumors. Photoacoustic tomography and optical imaging-guided surgical navigation may be a novel direction for improving the survival, quality of life, and disease management of pancreatic cancerpatients.
Authors: Thijs de Rooij; Martijn Z Lu; M Willemijn Steen; Michael F Gerhards; Marcel G Dijkgraaf; Olivier R Busch; Daan J Lips; Sebastiaan Festen; Marc G Besselink Journal: Ann Surg Date: 2016-08 Impact factor: 12.969
Authors: Laetitia E Lamberts; Maximillian Koch; Johannes S de Jong; Arthur L L Adams; Jürgen Glatz; Mariëtte E G Kranendonk; Anton G T Terwisscha van Scheltinga; Liesbeth Jansen; Jakob de Vries; Marjolijn N Lub-de Hooge; Carolien P Schröder; Annelies Jorritsma-Smit; Matthijs D Linssen; Esther de Boer; Bert van der Vegt; Wouter B Nagengast; Sjoerd G Elias; Sabrina Oliveira; Arjen J Witkamp; Willem P Th M Mali; Elsken Van der Wall; Paul J van Diest; Elisabeth G E de Vries; Vasilis Ntziachristos; Gooitzen M van Dam Journal: Clin Cancer Res Date: 2016-11-09 Impact factor: 12.531
Authors: Susanna W L de Geus; Leonora S F Boogerd; Rutger-Jan Swijnenburg; J Sven D Mieog; Willemieke S F J Tummers; Hendrica A J M Prevoo; Cornelis F M Sier; Hans Morreau; Bert A Bonsing; Cornelis J H van de Velde; Alexander L Vahrmeijer; Peter J K Kuppen Journal: Mol Imaging Biol Date: 2016-12 Impact factor: 3.488
Authors: Magali Godard; Fanny Gassiot; Angélina Acier; Pascal Finetti; Marion Rubis; Jonathan Nowak; François Bertucci; Juan L Iovanna; Richard Tomasini; Pascaline Lécorché; Guillaume Jacquot; Michel Khrestchatisky; Jamal Temsamani; Cédric Malicet; Sophie Vasseur; Fabienne Guillaumond Journal: Commun Biol Date: 2021-08-19